ÂÜÀòÂÒÂ×

Krishnan Nandabalan is the current chairman, president, and CEO at Invea Therapeutics. Krishnan has also previously served as the VP of Corporate Development at Genaissance Pharmaceuticals from January 1998 to December 2005 and as group leader of functional genomics at CuraGen Corporation from January 1995 to September 1998. Nandabalan has a long history of experience in the biotech industry, making him well-suited for their current role at Invea Therapeutics.

Krishnan Nandabalan has a Ph.D. from the Indian Institute of Science (IISc) in Biochemistry and Molecular Biology. Krishnan was a Post Doctoral Fellow at Yale University in Yeast Genetics and at the University of Kentucky in Biochemistry and Molecular Biology. Krishnan also has a BSc and MSc from Tamil Nadu Agricultural University in Microbiology.

Some direct reports include Patricia Spera - VP, Clinical Operations, Michael Aiello - CFO, and Salvatore Alesci - Chief Scientific Officer.